<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2004-10-1-12-15</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-951</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Клиническое значение гомоцистеинемии (обзор литературы)</article-title><trans-title-group xml:lang="en"><trans-title>Clinical value of homocysteinemia (a review of literature)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баранова</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Baranova</surname><given-names>Ye. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Большакова</surname><given-names>О. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Bolshakova</surname><given-names>O. O.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>СПбГМУ им. акад. И.П.Павлова</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>28</day><month>02</month><year>2004</year></pub-date><volume>10</volume><issue>1</issue><fpage>12</fpage><lpage>15</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Баранова Е.И., Большакова О.О., 2004</copyright-statement><copyright-year>2004</copyright-year><copyright-holder xml:lang="ru">Баранова Е.И., Большакова О.О.</copyright-holder><copyright-holder xml:lang="en">Baranova Y.I., Bolshakova O.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/951">https://htn.almazovcentre.ru/jour/article/view/951</self-uri></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Шевченко O.П., Олефриенко Г.А. Гипергомоцистеинемия и ее клиническое значение.Лаборатория. 2002; 1:3-7-</mixed-citation><mixed-citation xml:lang="en">Шевченко O.П., Олефриенко Г.А. Гипергомоцистеинемия и ее клиническое значение.Лаборатория. 2002; 1:3-7-</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Blacber J, Benetos A, Kirzin J et al. Relation of plasma homocysteine to cardiovascular mortality in a French population. Am J Cardiol 2002; 90 (6): 591 -5.</mixed-citation><mixed-citation xml:lang="en">Blacber J, Benetos A, Kirzin J et al. Relation of plasma homocysteine to cardiovascular mortality in a French population. Am J Cardiol 2002; 90 (6): 591 -5.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Booth G, Wang E. Preventive health care, 2000 update: screening and management ofhyperhomocysteinemia for the prevention of coronary artery disease events. CMA f2000; 163 (I): 21-9.</mixed-citation><mixed-citation xml:lang="en">Booth G, Wang E. Preventive health care, 2000 update: screening and management ofhyperhomocysteinemia for the prevention of coronary artery disease events. CMA f2000; 163 (I): 21-9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bots M, Launer L, Lindemans J et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. The Rotterdam Study. Arch Intern Med 1999; 159:38-44-</mixed-citation><mixed-citation xml:lang="en">Bots M, Launer L, Lindemans J et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. The Rotterdam Study. Arch Intern Med 1999; 159:38-44-</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Brophy J. The edpidemiology of acute myocardial infarction and ischemic heart disease in Canada: data from 1976 to 1991. Can J Cardiol 1997; 13: 74—178.</mixed-citation><mixed-citation xml:lang="en">Brophy J. The edpidemiology of acute myocardial infarction and ischemic heart disease in Canada: data from 1976 to 1991. Can J Cardiol 1997; 13: 74—178.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Cappuccio F, Bell R, Perry I et al. Homocysteine levels in men and women of different ethnic and cultural background living in England. Atherosclerosis 2002;164 (I): 95-102.</mixed-citation><mixed-citation xml:lang="en">Cappuccio F, Bell R, Perry I et al. Homocysteine levels in men and women of different ethnic and cultural background living in England. Atherosclerosis 2002;164 (I): 95-102.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Carey M, Donovan D, FitzGerald O. McAulcy F. Homocystinuria. A ctinical and pathological study of nine subjects in six families. AmJ Med 1968; 45: 7-25.</mixed-citation><mixed-citation xml:lang="en">Carey M, Donovan D, FitzGerald O. McAulcy F. Homocystinuria. A ctinical and pathological study of nine subjects in six families. AmJ Med 1968; 45: 7-25.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chen C, Surowiec S'. Morsy A, Ma M. Intraperitoneal infusion of homocysteine increases intimai hyperplasia in balloon-injured rat carotid arteries. Atherosclerosis 2002; 160 (I): 103-14-</mixed-citation><mixed-citation xml:lang="en">Chen C, Surowiec S'. Morsy A, Ma M. Intraperitoneal infusion of homocysteine increases intimai hyperplasia in balloon-injured rat carotid arteries. Atherosclerosis 2002; 160 (I): 103-14-</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:114-55·</mixed-citation><mixed-citation xml:lang="en">Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:114-55·</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Coppola A, Davi G, De Stefano V et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin Tbromb Hemost 2000; 26:243-54.</mixed-citation><mixed-citation xml:lang="en">Coppola A, Davi G, De Stefano V et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin Tbromb Hemost 2000; 26:243-54.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Den HeiJer M, Koster T, Blom H et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334 (12): 759-62.</mixed-citation><mixed-citation xml:lang="en">Den HeiJer M, Koster T, Blom H et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334 (12): 759-62.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Falcon C, Cattaneo M. Panzeri D et al. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14:1080-3.</mixed-citation><mixed-citation xml:lang="en">Falcon C, Cattaneo M. Panzeri D et al. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14:1080-3.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Fu W, Dudman N, Perry M, Wang X. Homocysteinemia attenuates hemodynamic responses to nitric oxide in vivo. Atherosclerosis 2002; 161 (I): 169-76.</mixed-citation><mixed-citation xml:lang="en">Fu W, Dudman N, Perry M, Wang X. Homocysteinemia attenuates hemodynamic responses to nitric oxide in vivo. Atherosclerosis 2002; 161 (I): 169-76.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Genser D. Homocysteine, vitamins, and restenosis after percutaneous coronary intervention. Cardiovasc Rev Rep 2003; 24 (5): 253-8.</mixed-citation><mixed-citation xml:lang="en">Genser D. Homocysteine, vitamins, and restenosis after percutaneous coronary intervention. Cardiovasc Rev Rep 2003; 24 (5): 253-8.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Graham M, Daly L, Refsum H et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted actionproject.JAMA 1997; 277 (22): 1775-81.</mixed-citation><mixed-citation xml:lang="en">Graham M, Daly L, Refsum H et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted actionproject.JAMA 1997; 277 (22): 1775-81.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Grubben M, Boers G, Blom H et al. Unfiltered coffee increases plasma homocysteine concentration in healthy volunteers: a randomized trial. Am J ClinNutr 1997; 71 (2): 480-4.</mixed-citation><mixed-citation xml:lang="en">Grubben M, Boers G, Blom H et al. Unfiltered coffee increases plasma homocysteine concentration in healthy volunteers: a randomized trial. Am J ClinNutr 1997; 71 (2): 480-4.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hainaut PJaumotte C, Verhelst D et at. Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res 2002; 106 (2): 121-5·</mixed-citation><mixed-citation xml:lang="en">Hainaut PJaumotte C, Verhelst D et at. Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res 2002; 106 (2): 121-5·</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hak E, Bak A, Lindemans J et al. The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled study. Atherosclerosis 2001; 158 (2): 437-43.</mixed-citation><mixed-citation xml:lang="en">Hak E, Bak A, Lindemans J et al. The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled study. Atherosclerosis 2001; 158 (2): 437-43.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hansram М, Gillespie J, Stansby G. Homocysteine in myointimal hyperplasia. EurJ Vasc Endovasc Surg 2002; 23:3-10.</mixed-citation><mixed-citation xml:lang="en">Hansram М, Gillespie J, Stansby G. Homocysteine in myointimal hyperplasia. EurJ Vasc Endovasc Surg 2002; 23:3-10.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Harker L, Ross R, Slichter S, Scott C. Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974; 291:537-43-</mixed-citation><mixed-citation xml:lang="en">Harker L, Ross R, Slichter S, Scott C. Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974; 291:537-43-</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hoffman M, Kohl B, Zumbach M et al. Hyperhomocyst(e)inemia and endothelial dysfunction in 1DDM. Diabetes Care 1998; 21:841-8.</mixed-citation><mixed-citation xml:lang="en">Hoffman M, Kohl B, Zumbach M et al. Hyperhomocyst(e)inemia and endothelial dysfunction in 1DDM. Diabetes Care 1998; 21:841-8.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Janson J, Galarza C, Muraa A et al. Prevalence of hyperhomocysteinemia in an elderly population. AmJ Hypertens 2002; 15 (I): 394-7.</mixed-citation><mixed-citation xml:lang="en">Janson J, Galarza C, Muraa A et al. Prevalence of hyperhomocysteinemia in an elderly population. AmJ Hypertens 2002; 15 (I): 394-7.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kahleová R, Palyzova D, Zvara K et al. Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypetens 2002; 15 (10): 857-64.</mixed-citation><mixed-citation xml:lang="en">Kahleová R, Palyzova D, Zvara K et al. Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypetens 2002; 15 (10): 857-64.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kanani P, Sinkey C, Browning R et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 1999; 100:1161-8.</mixed-citation><mixed-citation xml:lang="en">Kanani P, Sinkey C, Browning R et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 1999; 100:1161-8.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kark J, Selhub J, Adler B et al. Nonfasting plasma total homocysteine level and mortality in middle-aged arid elderly men and women in Jerusalem.Ann Int Med 1999; 131 (5): 321-30.</mixed-citation><mixed-citation xml:lang="en">Kark J, Selhub J, Adler B et al. Nonfasting plasma total homocysteine level and mortality in middle-aged arid elderly men and women in Jerusalem.Ann Int Med 1999; 131 (5): 321-30.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kaye J, Stanton K, McCann W, Vasikaran S. Homocysteine,folate, MTGFR genotype and vascular morbidity in diabetic subjects. Clin Sci 2002; 102:263-</mixed-citation><mixed-citation xml:lang="en">Kaye J, Stanton K, McCann W, Vasikaran S. Homocysteine,folate, MTGFR genotype and vascular morbidity in diabetic subjects. Clin Sci 2002; 102:263-</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kuch B, Bobak M, FobkerM et al. Association between homocysteine and coagulation factors - a cross-sectional study in two populations of Central Ewope. Atherosclerosis 2001; 103 (4): 265-73-</mixed-citation><mixed-citation xml:lang="en">Kuch B, Bobak M, FobkerM et al. Association between homocysteine and coagulation factors - a cross-sectional study in two populations of Central Ewope. Atherosclerosis 2001; 103 (4): 265-73-</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Lim S, Kim M, Park K et al. Correlation of plasma homocysteine and mytochondrial DNA content in peripheral blood of healthy women. Atherosclerosis 2001; 158 (2): 399-405-</mixed-citation><mixed-citation xml:lang="en">Lim S, Kim M, Park K et al. Correlation of plasma homocysteine and mytochondrial DNA content in peripheral blood of healthy women. Atherosclerosis 2001; 158 (2): 399-405-</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Loscalo J. The oxidant stress of hyperhomocyst(e)inemia.J Clin Invest 1996; 98 (I):5-7.</mixed-citation><mixed-citation xml:lang="en">Loscalo J. The oxidant stress of hyperhomocyst(e)inemia.J Clin Invest 1996; 98 (I):5-7.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Mager Ą Battler A, Birnbaum Y et al. Plasma homocysteine, methylenetetrahy-drofolate reductase genotype, and age at onset of symptoms of myocardial ischemia. Atheroscterosis 2002; 89 (8): 919-23.</mixed-citation><mixed-citation xml:lang="en">Mager Ą Battler A, Birnbaum Y et al. Plasma homocysteine, methylenetetrahy-drofolate reductase genotype, and age at onset of symptoms of myocardial ischemia. Atheroscterosis 2002; 89 (8): 919-23.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Marcucci R, Prisco D, Brunelli T et al. Tissue factor and homocysteine levels in ischemic heart disease are associated with angiogrpbicaüy documented clinical recurrences after coronary angioplasty. Thtvmb Haemost2000; 83:826-32.</mixed-citation><mixed-citation xml:lang="en">Marcucci R, Prisco D, Brunelli T et al. Tissue factor and homocysteine levels in ischemic heart disease are associated with angiogrpbicaüy documented clinical recurrences after coronary angioplasty. Thtvmb Haemost2000; 83:826-32.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Mayer EJacobsen D, Robinson K Homocysteine and coronary atherosclerosis. JAm Coll Cardiol 1996; 27:517-27.</mixed-citation><mixed-citation xml:lang="en">Mayer EJacobsen D, Robinson K Homocysteine and coronary atherosclerosis. JAm Coll Cardiol 1996; 27:517-27.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">McCuUy K Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. AmJ Pathol 1969; 56:111-28.</mixed-citation><mixed-citation xml:lang="en">McCuUy K Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. AmJ Pathol 1969; 56:111-28.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">McCully K Chemical pathology of homocysteine. Atberogenesis. Anal Clin Lab Sci 1993; 23:477-93.</mixed-citation><mixed-citation xml:lang="en">McCully K Chemical pathology of homocysteine. Atberogenesis. Anal Clin Lab Sci 1993; 23:477-93.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Merki-Feld G, lmthum B, KeUer P. Effects of oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism. Metabolism 2002; 51 (9): 1216-21.</mixed-citation><mixed-citation xml:lang="en">Merki-Feld G, lmthum B, KeUer P. Effects of oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism. Metabolism 2002; 51 (9): 1216-21.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Moghadasian M, McManus B, Fröhlich J. Homocysteine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med 1997; 157:2299-308.</mixed-citation><mixed-citation xml:lang="en">Moghadasian M, McManus B, Fröhlich J. Homocysteine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med 1997; 157:2299-308.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Moreno H, Kuffaty J, Croce N et al. Homocysteinemia and its relation with risk factor for arterial hypertension. Am J Hypertens 2002; 15 (4, suppl. I ): P.A218.</mixed-citation><mixed-citation xml:lang="en">Moreno H, Kuffaty J, Croce N et al. Homocysteinemia and its relation with risk factor for arterial hypertension. Am J Hypertens 2002; 15 (4, suppl. I ): P.A218.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Morita H, Kurihara H, Sugfyama T et al. Polymorphism of the methionine synthase gene. Association with homocysteine metabolism and late-onset vascular disease in the Japanese population. Arterioscler Thromb VascBiol 1999; 19: 298-302.</mixed-citation><mixed-citation xml:lang="en">Morita H, Kurihara H, Sugfyama T et al. Polymorphism of the methionine synthase gene. Association with homocysteine metabolism and late-onset vascular disease in the Japanese population. Arterioscler Thromb VascBiol 1999; 19: 298-302.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Morita H, Taguchi J, Kurihara H et al. Genetic polymorphism of 5,10-methyl· enetetrahydrofolate reductase as a risk factor for coronary artery disease. Circulation 1997;95:2032-6.</mixed-citation><mixed-citation xml:lang="en">Morita H, Taguchi J, Kurihara H et al. Genetic polymorphism of 5,10-methyl· enetetrahydrofolate reductase as a risk factor for coronary artery disease. Circulation 1997;95:2032-6.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Ou T, Yamakawa-Kobayashi K. Arinami T et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphism are independent riskfactors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998; 137:23-8.</mixed-citation><mixed-citation xml:lang="en">Ou T, Yamakawa-Kobayashi K. Arinami T et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphism are independent riskfactors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998; 137:23-8.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Rees M, Rodgers G. Homocysteinemia: association of a metabolic disorders with vascular disease and thrombosis. Thromb Res 1993; 71:337-59-</mixed-citation><mixed-citation xml:lang="en">Rees M, Rodgers G. Homocysteinemia: association of a metabolic disorders with vascular disease and thrombosis. Thromb Res 1993; 71:337-59-</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Reyes-Engel Ą, Morel M, Aranda F et al. Plasma homocysteine levels, C667T polymorphism of metbylenetetrahydrofalate reductasa gene, plasma renin activity and cardiovascular risk. AmJ Hypertens 2002; I4 (4,suppl. I): P.AÎ54·</mixed-citation><mixed-citation xml:lang="en">Reyes-Engel Ą, Morel M, Aranda F et al. Plasma homocysteine levels, C667T polymorphism of metbylenetetrahydrofalate reductasa gene, plasma renin activity and cardiovascular risk. AmJ Hypertens 2002; I4 (4,suppl. I): P.AÎ54·</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345 (22): 1593-600.</mixed-citation><mixed-citation xml:lang="en">Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345 (22): 1593-600.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Schnyder G,Roffi M, Flammer Yet al. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur HeartJ2002; 23: 726-33.</mixed-citation><mixed-citation xml:lang="en">Schnyder G,Roffi M, Flammer Yet al. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur HeartJ2002; 23: 726-33.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Stampfer M, Malinow M. Can lowering homocysteine levels reduce cardiovascular risk? N EnglJ Med 1995; 332:328-9.</mixed-citation><mixed-citation xml:lang="en">Stampfer M, Malinow M. Can lowering homocysteine levels reduce cardiovascular risk? N EnglJ Med 1995; 332:328-9.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Stampfer M, Malinow M, WiUettWet alA prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992%;268: 877-81.</mixed-citation><mixed-citation xml:lang="en">Stampfer M, Malinow M, WiUettWet alA prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992%;268: 877-81.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Stein J, Mc Bride P. Hyperhomocysteinemia and atherosclerotic vascular disease. Arch Intern Med 1998; 158: 1301-6.</mixed-citation><mixed-citation xml:lang="en">Stein J, Mc Bride P. Hyperhomocysteinemia and atherosclerotic vascular disease. Arch Intern Med 1998; 158: 1301-6.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Tawakol Ą Omland T1 Gerhard M et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependant vasodilatation in humans. Curculation 1997;95:1119-21.</mixed-citation><mixed-citation xml:lang="en">Tawakol Ą Omland T1 Gerhard M et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependant vasodilatation in humans. Curculation 1997;95:1119-21.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Tawakol Ą Forgione M, Stuehlinger M et al. Homocysteine impairs coronary mierovascular dilatorjunction in humans.JACC 2002; 40 (6): 1051</mixed-citation><mixed-citation xml:lang="en">Tawakol Ą Forgione M, Stuehlinger M et al. Homocysteine impairs coronary mierovascular dilatorjunction in humans.JACC 2002; 40 (6): 1051</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Griend R, Haas F, Duran M et al. Methionine loading test is necessary for detection of hyperhomocysteinemia J Lab ClinMed 1996; 132 ( I): 67-72.</mixed-citation><mixed-citation xml:lang="en">Van der Griend R, Haas F, Duran M et al. Methionine loading test is necessary for detection of hyperhomocysteinemia J Lab ClinMed 1996; 132 ( I): 67-72.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Veerkamp M, de GraafJ, den HeijerM et al. Plasma homocysteine in subjects withfamilial combined by perlipidetnia. 2003; 166 (I): 111-7.</mixed-citation><mixed-citation xml:lang="en">Veerkamp M, de GraafJ, den HeijerM et al. Plasma homocysteine in subjects withfamilial combined by perlipidetnia. 2003; 166 (I): 111-7.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Wald N, Watt H, Law Meta L Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7. '</mixed-citation><mixed-citation xml:lang="en">Wald N, Watt H, Law Meta L Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7. '</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X, Duarte N, Cai H et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-basespopulation. Atherosclerosis 1999; 146:133-40.</mixed-citation><mixed-citation xml:lang="en">Wang X, Duarte N, Cai H et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-basespopulation. Atherosclerosis 1999; 146:133-40.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Warren C. Emergent cardiovascular risk factor: Homocysteine. Prog Cardio-vascNurs 2002; 17-35—41.</mixed-citation><mixed-citation xml:lang="en">Warren C. Emergent cardiovascular risk factor: Homocysteine. Prog Cardio-vascNurs 2002; 17-35—41.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Welch G, Loscalo J. Homocysteine and atherosclerosis. New EnglJ Med 1998; 338 (15): 1042-50.</mixed-citation><mixed-citation xml:lang="en">Welch G, Loscalo J. Homocysteine and atherosclerosis. New EnglJ Med 1998; 338 (15): 1042-50.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Welch G, Upchurch G, Loscalo J. Hyperbomoceyst(e)inemia and atherothrombosis. Ann NYAcad Sci 1997; 811:48-58.</mixed-citation><mixed-citation xml:lang="en">Welch G, Upchurch G, Loscalo J. Hyperbomoceyst(e)inemia and atherothrombosis. Ann NYAcad Sci 1997; 811:48-58.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Wotherspoon F, Laight D, Shaw K, Cummings M. Homocysteine, endothelial dysfunction and oxidative stress in type I diabetes mellitus. BrJ Diabetes Vasc Dis 2003; 3 (5): 334-40.</mixed-citation><mixed-citation xml:lang="en">Wotherspoon F, Laight D, Shaw K, Cummings M. Homocysteine, endothelial dysfunction and oxidative stress in type I diabetes mellitus. BrJ Diabetes Vasc Dis 2003; 3 (5): 334-40.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
